Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

South Africa has played a historic, global role in scientific research, from COVID-19 vaccines to HIV. Now that's under ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and ...